JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264670

Human PRKCI (PKC iota) knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

PRKCI KO cell line available to order. KO validated. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 5. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Human PRKCI (PKC iota) knockout HeLa cell line (AB264670)
  • WB

Lab

Western blot - Human PRKCI (PKC iota) knockout HeLa cell line (AB264670)

False colour image of Western blot : Anti-PRKCI antibody staining at 1/500 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, the antibody was shown to bind specifically to PRKCI. A band was observed at 72 kDa in wild-type HeLa cell lysates with no signal observed at this size in PRKCI knockout cell line ab264670 (knockout cell lysate ab258604). To generate this image, wild-type and PRKCI knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.

false

Sanger Sequencing - Human PRKCI (PKC iota) knockout HeLa cell line (AB264670)
  • Sanger seq

Unknown

Sanger Sequencing - Human PRKCI (PKC iota) knockout HeLa cell line (AB264670)

Homozygous : Insertion of the selection cassette in exon 5.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: Insertion of the selection cassette in exon 5

Disease

Adenocarcinoma

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264670-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264670-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264670 Human PRKCI (PKC iota) knockout HeLa cell line", "number":"AB264670-CMP01" } ] }, "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab264670-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab255448 Human wild-type HeLa cell line", "number":"AB264670-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab264670 Human PRKCI (PKC iota) knockout HeLa cell line", "number":"AB264670-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264670-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264670 Human PRKCI (PKC iota) knockout HeLa cell line", "number":"AB264670-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264670-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264670 Human PRKCI (PKC iota) knockout HeLa cell line", "number":"AB264670-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
PRKCI
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Protein Kinase C (PKC) iota also known by its gene symbol PRKCI is an atypical member of the PKC family. It has a molecular mass of approximately 74 kDa. PKC iota does not respond to calcium and is insensitive to diacylglycerol and phorbol esters which differentiates it from other classical PKC family members. The protein initiates cell survival and proliferation pathways and is primarily expressed in brain heart liver and skeletal muscle tissues indicating its extensive role across various biological functions.
Biological function summary

PKC iota acts as an important player in regulating cell polarity and protecting cells from stress-induced apoptosis. It forms part of the Par6-Par3-PKC iota complex which is important for maintaining cell polarity and directional migration. This complex is essential for neural tube closure during embryonic development and in establishing cell polarity across diverse cell types. PKC iota also contributes to the regulation of microtubule organization reinforcing its vital role in maintaining cellular architecture.

Pathways

PKC iota is important in the NF-kB signaling pathway and the PI3K/AKT pathway. In the NF-kB pathway PKC iota activates IkB kinase leading to NF-kB transcriptional activity which promotes cell survival. In the PI3K/AKT pathway PKC iota contributes to cell growth and survival working closely with AKT proteins. These pathways highlight its involvement in processes like proliferation survival and cellular response to external stimuli.

PKC iota has a significant connection to cancer and neurological disorders. Its overexpression has been observed in several cancers such as lung and prostate cancer where it is often associated with poor prognosis. PKC iota's role in the maintenance of cell polarity and survival links it to malignant cell behavior. Additionally in neurological disorders like Alzheimer's disease alterations in PKC iota activity have been related to synaptic dysfunctions. Connections to proteins such as AKT and NF-kB in these conditions highlight its potential as a therapeutic target.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com